Quarterly report pursuant to Section 13 or 15(d)

Revenue and Accounts Receivable - Performance Obligations (Details)

v3.10.0.1
Revenue and Accounts Receivable - Performance Obligations (Details) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2018-04-01 - Biopharma Services
$ in Millions
Sep. 30, 2018
USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue, remaining performance obligation $ 32.4
Revenue, remaining performance obligation, expected timing of satisfaction, period 2 years